U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07129239) titled 'High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)' on July 10.
Brief Summary: The purpose of this study is to compare two treatment frequencies using EYLEA(R) HD (aflibercept 8mg) in patients with wet age-related macular degeneration (wAMD) that are currently treated with EYLEA(R) (aflibercept 2mg).
EYLEA(R) HD is approved by Health Canada has been tested in large clinical trials involving thousands of patients around the world and has been shown effective in the treatment of wAMD. The treatment regimen used in these trials involved 3 initial monthly injections ...